Saphnelo (anifrolumab) is an FDA-approved medication for the treatment of systemic lupus erythematosus (SLE) in adults. Anifrolumab targets type I interferon receptor, which is overexpressed in many SLE patients, leading to inflammation and organ damage. The medication works by reducing inflammation and disease activity and has been shown to reduce flare rates and corticosteroid use in clinical trials. Anifrolumab is given as an intravenous infusion every four weeks and may have side effects such as nasopharyngitis, upper respiratory tract infections, and infusion reactions. Nonetheless, anifrolumab is a hopeful treatment option for SLE patients who need effective therapies.